



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 333 858 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

Note: Bibliography reflects the latest situation

- (15) Correction information:
Corrected version no 1 (W1 B1)
INID code(s) 73
- (48) Corrigendum issued on:
14.06.2006 Bulletin 2006/24
- (45) Date of publication and mention
of the grant of the patent:
08.02.2006 Bulletin 2006/06
- (21) Application number: **01983349.0**
- (22) Date of filing: **31.10.2001**
- (51) Int Cl.:
A61K 39/39 (2006.01) **A61K 39/00** (2006.01)
A61K 39/29 (2006.01) **A61K 9/00** (2006.01)
A61K 9/127 (2006.01) **A61P 15/00** (2006.01)
- (86) International application number:
PCT/CA2001/001530
- (87) International publication number:
WO 2002/038175 (16.05.2002 Gazette 2002/20)

(54) **VACCINES WITH ENHANCED IMMUNE RESPONSE AND METHODS FOR THEIR PREPARATION**
IMPfstoffe mit erhöhter Immunantwort und Verfahren zur deren Herstellung
Vaccins à réponse immunitaire accrue et leurs procédés de préparation

- | | |
|---|---|
| <p>(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR</p> <p>(30) Priority: 07.11.2000 US 246075 P
24.07.2001 US 307159 P</p> <p>(43) Date of publication of application:
13.08.2003 Bulletin 2003/33</p> <p>(73) Proprietor: ImmunoVaccine Technologies Inc.
Halifax,
Nova Scotia B3J 3R1 (CA)</p> <p>(72) Inventors:
• BROWN, Robert, George
Dartmouth, Nova Scotia B2W 2C4 (CA)
• POHAJDAK, Bill
Dartmouth, Nova Scotia B2V 2C4 (CA)
• KIMMINS, Warwick, Charles
Halifax, Nova Scotia B3H 1A5 (CA)</p> <p>(74) Representative: Baldock, Sharon Claire et al
BOULT WADE TENNANT,
Verulam Gardens
70 Gray's Inn Road
London WC1X 8BT (GB)</p> | <p>(56) References cited:
WO-A-00/37100 WO-A-92/00081
US-A- 5 422 109 US-A- 5 736 141</p> <ul style="list-style-type: none">• H. NASH ET AL.: "Formulation of a potential antipregnancy vaccine based on the beta-subunit of human chorionic gonadotropin (beta-hCG). II. Use of compounds of the muramyl dipeptide (MDP) family as adjuvants." JOURNAL OF REPRODUCTIVE IMMUNOLOGY, vol. 7, no. 2, 1985, pages 151-162, XP001053240 Amsterdam, The Netherlands• A. HILBERT ET AL.: "Biodegradable microspheres containing influenza A vaccine: immune response in mice." VACCINE, vol. 17, no. 9-10, March 1999 (1999-03), pages 1065-1073, XP004158227 Guildford, GB• R. GUPTA ET AL.: "Adjuvants for human vaccines - current status, problems and future prospects." VACCINE, vol. 13, no. 14, October 1995 (1995-10), pages 1263-1276, XP004057427 Guildford, GB• D. PYE ET AL.: "Selection of an adjuvant for vaccination with the malaria antigen, MSA-2." VACCINE, vol. 15, no. 9, June 1987 (1987-06), pages 1017-1023, XP004115370 Guildford, GB• ALLISON A. METHODS vol. 19, no. 1, 1999, pages 87 - 93• LAWRENCE G.W. ET AL VACCINE vol. 15, no. 2, 1997, pages 176 - 178 |
|---|---|

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 333 858 B8

- | | |
|--|--|
| <ul style="list-style-type: none">• STONE H.D. AVIAN DIS. vol. 37, no. 2, 1993, pages 399 - 405• YARKONI E. ET AL CANCER RES. vol. 39, no. 5, 1979, pages 1518 - 1520• EGHAFONA N.O. VACCINE vol. 14, no. 17-18, 1996, pages 1518 - 1520 | <ul style="list-style-type: none">• CHANG J.C.C. ET AL ADVANCED DRUG DELIVERY REVIEWS vol. 32, 1998, pages 173 - 186 |
|--|--|